1. Home
  2. NVEC vs CLLS Comparison

NVEC vs CLLS Comparison

Compare NVEC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NVE Corporation

NVEC

NVE Corporation

HOLD

Current Price

$68.33

Market Cap

368.2M

Sector

Technology

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.58

Market Cap

384.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVEC
CLLS
Founded
1989
1999
Country
United States
France
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
368.2M
384.3M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
NVEC
CLLS
Price
$68.33
$3.58
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
21.7K
43.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
5.85%
N/A
EPS Growth
N/A
N/A
EPS
2.12
N/A
Revenue
$25,874,694.00
N/A
Revenue This Year
N/A
$40.37
Revenue Next Year
N/A
N/A
P/E Ratio
$32.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.50
$1.10
52 Week High
$82.30
$5.48

Technical Indicators

Market Signals
Indicator
NVEC
CLLS
Relative Strength Index (RSI) 51.63 40.77
Support Level $63.56 $3.41
Resistance Level $74.14 $3.77
Average True Range (ATR) 2.59 0.19
MACD 0.00 -0.03
Stochastic Oscillator 46.02 13.54

Price Performance

Historical Comparison
NVEC
CLLS

About NVEC NVE Corporation

NVE Corp develops and sells devices that use spintronics, a nanotechnology that relies on electron spin. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: